scorecardresearch

Lupin launches anti-seizure tablets in United States

According to IQVIA MAT October 2022, Rufinamide Tablets (RLD Banzel) had estimated annual sales of USD 138 million in the United States.

Lupin launches anti-seizure tablets in United States
The drug will be available in one strength with a fixed dose to be taken once daily. (File)

Global pharma major Lupin Limited on Monday announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel Tablets, 200 mg and 400 mg, of Eisai Inc.

According to IQVIA MAT October 2022, Rufinamide Tablets (RLD Banzel) had estimated annual sales of USD 138 million in the United States.

An anticonvulsant medication, Rufinamide is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders.

The drug was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

ALSO READ | Lupin launches nasal drug for breathing problems in United States

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

First published on: 05-12-2022 at 02:51:56 pm